Join and network with over 250 industry leaders at Discovery US 2023, where we will address the latest advancements in target identification, validation and HIT optimisation. The 2-day programme addresses drug discovery in new modalities such as protein degradation, and case studies on the integration of screening approaches in phenotypic and genomics-based discovery, Organ-on-a-chip and 3D modelling.
Topics: protein degradation, integration of screening approaches in phenotypic and genomics-based discovery, Organ-on-a-chip and 3D modelling.